DOW CROSSES 40,000 MARK FOR THE FIRST TIME

All three major indices post weekly wins as meme rally fizzles out

JNJ Jan 2025 125.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

27.00

0.00

(0.00%)

As of 11:10AM EDT. Market open.

Loading interactive chart...

Zacks
J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition
Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.
Zacks
Johnson & Johnson (JNJ) Up 5.5% Since Last Earnings Report: Can It Continue?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reuters
UPDATE 1-Johnson & Johnson to acquire Proteologix for $850 million
Johnson & Johnson said on Thursday it would acquire Proteologix for $850 million in cash, as it looks to gain access to the privately held company's experimental atopic dermatitis treatments. Proteologix's antibody PX128 is ready to enter early-stage development for moderate to severe atopic dermatitis, commonly referred to as eczema, and moderate to severe asthma. PX130, its other antibody, is in preclinical development for moderate to severe atopic dermatitis.